14.11
+0.04
+(0.28%)
At close: April 17 at 5:35:09 PM GMT+2
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | 2 | 2 |
Avg. Estimate | 0 | 0 | -0.37 | 0.81 |
Low Estimate | 0 | 0 | -0.67 | 0.07 |
High Estimate | 0 | 0 | -0.07 | 1.55 |
Year Ago EPS | -- | -- | -0.88 | -0.37 |
Revenue Estimate
Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 4 | 4 |
Avg. Estimate | 5.1M | 5.7M | 20.13M | 39.65M |
Low Estimate | 5.1M | 5.7M | 13.2M | 28.5M |
High Estimate | 5.1M | 5.7M | 25M | 48M |
Year Ago Sales | -- | -- | 9.03M | 20.13M |
Sales Growth (year/est) | -- | -- | 122.92% | 96.93% |
EPS Trend
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | -0.37 | 0.81 |
7 Days Ago | 0 | 0 | -0.41 | 0.92 |
30 Days Ago | 0 | 0 | -0.41 | 0.92 |
60 Days Ago | 0 | 0 | -0.38 | 0.92 |
90 Days Ago | 0 | 0 | -0.18 | 1.12 |
EPS Revisions
Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | 2 | -- |
Up Last 30 Days | -- | -- | 2 | -- |
Down Last 7 Days | -- | -- | -- | 2 |
Down Last 30 Days | -- | -- | -- | 2 |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
MEDCL.PA | -- | -- | 57.95% | 318.92% |
S&P 500 | 6.92% | 5.09% | 8.78% | 14.15% |
Related Tickers
4588.T Oncolys BioPharma Inc.
579.00
+6.04%
4565.T Nxera Pharma Co., Ltd.
850.00
+3.41%
4587.T PeptiDream Inc.
1,870.00
+3.03%
ALCLS.PA Cellectis S.A.
1.3500
+0.15%
DBV.PA DBV Technologies S.A.
1.3280
+3.59%
IPH.PA Innate Pharma S.A.
1.7480
-0.46%
ADOC.PA Adocia SA
3.8500
+2.67%
BSLN.SW Basilea Pharmaceutica AG
41.30
-0.96%
CAMX.ST Camurus AB (publ)
566.00
+0.62%
GLPG.AS Galapagos NV
21.84
+0.74%